Business Wire

Shippeo Announces Anand Medepalli as Chief Product Officer

14.12.2021 11:00:00 EET | Business Wire | Press release

Share

Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the appointment of Anand Medepalli as their Chief Product Officer to lead the company during a time of immense growth and support clients with an innovative vision of Shippeo’s product offering.

Anand has over 25 years of experience as a trusted advisor with leading companies in product strategies, commercial account strategies, and asset planning decisions in transportation, supply chain, and financial services. He has spent much of his career advising companies and defining innovative solutions to drive their growth. Before Shippeo, Anand was Head of AI Solutions at ServiceNow, following the acquisition of Element AI, where he was Head of Products. Previous to this experience, Anand worked for several years at Blue Yonder, as the VP of Retail Planning products.

"One look around and you know that supply chains are under stress. Shippers, carriers, and LSPs need unprecedented visibility into their supply chains to serve their customers, and they need solutions that give them accurate insights into their operations,” says newly appointed Chief Product Officer, Anand Medepalli. “Shippeo, with its right vision and impressive technology, is addressing this problem head-on for some very innovative and well-known customers, and delivering significant value to them. It was a no-brainer for me to join the talented Shippians as I understood that this was where I could indulge in my passion for supply chain, big data, machine learning and AI in one place and at the same time make a significant positive difference to our customers."

With over 100 customers, including global brands like Coca-Cola HBC, Faurecia, and Total, Shippeo offers a best-in-market ETA prediction in terms of accuracy and reliability as well as a more granular degree of multimodal tracking, right down to handling unit and goods levels, which supports all modes of transport including ocean, road, LTL and FTL. Shippeo's ambition is to be the leading supply chain operating system, enabling fully automated and sustainable supply chains across the world.

Lucien Besse, Shippeo’s Chief Operating Officer, welcomes Anand to the team. “We are thrilled to welcome Anand to the Shippeo executive leadership team. He brings great skills at the intersection of product strategy, AI, machine learning, and supply chain management to the company”, said Besse. “As the Chief Product Officer, he will set the product strategy to disrupt the supply chain visibility marketplace with innovative solutions, playing a key role in the company’s development and continued success. His intimate knowledge and experience within the market are invaluable, and he will no doubt be a great asset within our leadership team.”

More information

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Celine Bonniot, Field Marketing Director, Shippeo, celine.bonniot@shippeo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye